German pharmaceutical and healthcare company STADA Arzneimittel AG (STDAY.PK,STDAF.PK) said Tuesday that, on the occasion of today's Capital Markets Day, it intends to exceed the one billion euros mark in sales for branded products in the medium term, with additional acquisitions, progressing internationalization and centralized portfolio management.
The Executive Board of STADA affirmed its outlook for financial year 2014 with slight growth in Group sales, adjusted EBITDA and adjusted net income.
In light of current events, Dmitry Efimov, CEO STADA CIS, has informed the participants of market developments and trends in Russia and has highlighted the expectations of STADA's Executive Board regarding an upswing in the local business in the fourth quarter of the current financial year.
On 3rd March, the company said it expected further growth and confirmed the prognosis for financial year 2014 as given in 2010. According to this, Group sales of 2.15 billion euros, adjusted EBITDA of 430 million euros and adjusted net income of 215 million euros could be reached.
For comments and feedback contact: editorial@rttnews.com
Business News